The Brazilian National Institute of Industrial Property has granted a Family 4 patent covering lead compounds RECCE 327 and RECCE 529, with protection extending to 2041.
After more than 15 years of setbacks, Mesoblast has finally secured its first FDA approval, and early signs suggest the commercial rollout is gaining traction.